Last update 21 Mar 2024
Hyperlipoproteinemia Type IIb
Last update 21 Mar 2024
Basic Info
Synonyms Hyperbetalipoproteinemia with prebetalipoproteinemia, 2bｶﾞﾀｺｳﾘﾎﾟﾀﾝﾊﾟｸｹﾂｼｮｳ, Hyperlipoproteinemia, Frederickson type IIb + [50] |
Introduction Type IIb hyperlipoproteinemia is caused by mutation in the receptor-binding domain of APOLIPOPROTEIN B-100 which is a major component of LOW-DENSITY LIPOPROTEINS and VERY-LOW-DENSITY LIPOPROTEINS resulting in reduced clearance of these lipoproteins. It is characterized by both hypercholesterolemia and HYPERTRIGLYCERIDEMIA (combined hyperlipidemia). |
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
阿昔莫司胶囊在健康受试者中的单中心、单剂量、2制剂、2周期、2序列、开放、随机、交叉的平均生物等效性试验
[Translation] Single-center, single-dose, 2-formulation, 2-cycle, 2-sequence, open-label, randomized, crossover mean bioequivalence trial of acipimox capsules in healthy subjects
阿昔莫司胶囊（0.25g）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
[Translation] Randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of acipimox capsules (0.25g) under fasting and fed administration conditions in Chinese healthy subjects
阿昔莫司胶囊随机、开放、单剂量、两制剂、自身交叉对照设计在中国健康受试者中的生物等效性正式试验。
[Translation] A randomized, open-label, single-dose, two-dose, self-crossover control design formal bioequivalence trial of acipimox capsules in Chinese healthy subjects.
100 Clinical Results associated with Hyperlipoproteinemia Type IIb
Login to view more data
100 Translational Medicine associated with Hyperlipoproteinemia Type IIb
Login to view more data
Login to view more data
01 Mar 2019Clinica Chimica ActaQ3 · MEDICINE
Metabolic disorders and inflammation are associated with familial combined hyperlipemia
Q3 · MEDICINE
Article
Author: Diaz-Ruiz, Maria ; Martinez-Triguero, Maria L. ; Lopez-Ruiz, Antonio ; Fernandez-de la Cruz, Francis ; Banuls, Celia ; Hernandez-Mijares, Antonio
BACKGROUND:
Familial Combined Hyperlipidemia (FCH) is related to different metabolic disorders. The objective of this study was to evaluate the presence of alterations of hydrocarbonated metabolism and lipid profile together with inflammatory and adhesion molecules in subjects with FCH compared to controls.
METHODS:
75 HFC patients and 75 healthy individuals were studied. Glucose, insulin, HOMA-IR index and lipid parameters, in addition to anti-oxidized LDL antibodies (Anti ox-LDL), small and dense LDL (sdLDL) and HDL subfractions, proinflammatory cytokines and adhesion molecules were measured.
RESULTS:
FCH patients showed higher levels of hydrocarbonated metabolism parameters, total cholesterol, triglycerides, LDLc, Apolipoprotein B and non-HDLc (p < .001), and lower levels of HDLc (p < .001) and Apolipoprotein AI (p < .05) than controls. In addition, the inflammatory markers hsCRP, IL-6, IL-8, P-selectin, E-selectin and ICAM were all higher with (p < .05) respect to controls. The increase of sdLDL was correlated with the presence of IR and IL-6 levels. Significant differences in diameter and percentage of phenotype B LDL, small HDL subfractions and Anti ox-LDL were also detected between patients and controls.
CONCLUSIONS:
The lipid characteristics of FCH are confirmed by IR and a low grade inflammatory state in patients, and are associated with the predominance of sdLDL and Anti ox-LDL.
01 Feb 2015Metabolism, Clinical and ExperimentalQ1 · MEDICINE
Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls
Q1 · MEDICINE
Article
Author: de Vries, Marijke A. ; Alipour, Arash ; Klop, Boudewijn ; van de Geijn, Gert-Jan M. ; Janssen, Hans W. ; Njo, Tjin L. ; van der Meulen, Noelle ; Rietveld, Arie P. ; Liem, Anho H. ; Westerman, Elsbeth M. ; de Herder, Wouter W. ; Castro Cabezas, Manuel
BACKGROUND:
Leukocyte activation has been associated with vascular complications in type 2 diabetes mellitus (T2DM). Hyperglycemia may be involved in this leukocyte activation. Our aim was to investigate the role of elevated glucose concentrations on leukocyte activation in patients with a wide range of insulin sensitivity.
METHODS:
Leukocyte activation was determined after ingestion of 75 gram glucose in subjects with T2DM, familial combined hyperlipidemia (FCH) and healthy controls. Leukocyte activation markers were measured by flow cytometry. Postprandial changes were calculated as the area under the curve (AUC), and the incremental area under the curve corrected for baseline values (dAUC).
RESULTS:
51 Subjects (20 T2DM, 17 FCH and 14 controls) were included. Fasting neutrophil CD66b expression and CD66b-AUC were respectively 36% and 39% higher in T2DM patients than in controls (p=0.004 and p=0.003). Fasting neutrophil CD66b expression correlated positively with glucose-AUC (Spearman's rho 0.481, p<0.001) and HbA1c (rho 0.433, p=0.002). Although fasting monocyte CD11b expression was not significantly different between subjects, monocyte CD11b-AUC was 26% higher in T2DM than in controls (p=0.006). Similar trends were observed for FCH patients. Monocyte CD11b-dAUC correlated positively with glucose-AUC (rho 0.322, p=0.022) and HbA1c (rho 0.319, p=0.023).
CONCLUSIONS:
These data suggest that both acute and chronic hyperglycemia, associated with insulin resistance as seen in T2DM and FCH, are involved in the increased fasting and postprandial leukocyte activation observed in these conditions.
20 Apr 2013Archives of Medical ScienceQ4 · MEDICINE
Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate
Q4 · MEDICINE
ArticleOA
Author: Cicero, Arrigo F. G. ; Derosa, Giuseppe ; Maffioli, Pamela ; Reggi, Alessandra ; Grandi, Elisa ; Borghi, Claudio
INTRODUCTION:
Familial combined hyperlipoproteinemia (FCHL) is a very common and aggressive genetic mixed hyperlipoproteinemia, with many features similar to that of the metabolic syndrome (MS). We aimed to evaluate whether the presence of the MS per se could account for a significant part of the elevated cardiovascular disease (CVD) risk associated with FCHL.
MATERIAL AND METHODS:
A retrospective cross-sectional evaluation of MS features' influence on CVD prevalence in a large sample of adult Italian FCHL affected patients (64 familial clusters; 867 subjects) was carried out.
RESULTS:
Age is associated with early cardiovascular complications, both in men (OR 1.08, 95% CI: 1.05-1.11, p < 0.0001) and in women (OR 1.09, 95% CI: 1.04-1.13, p = 0.0001). No MS component appears to be related to cardiovascular complications in men, whilst only low plasma high-density lipoprotein cholesterol (HDL-C) shows such a relation in women. Among non-MS parameters, only low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) plasma levels are significantly associated with early cardiovascular complications in male FCHL patients (LDL-C: OR 2.24, 95% CI: 1.02-4.91, p = 0.04; Lp(a): OR 4.64, 95% CI: 1.85-11.62, p = 0.001), but not in women (LDL-C: OR 1.83, 95% CI 0.53-6.34, p = 0.34; Lp(a): OR 3.65, 95% CI: 0.89-14.97, p = 0.07).
CONCLUSIONS:
Our data support the hypothesis that MS is not associated with a higher prevalence of cardiovascular complications in FCHL affected subjects, probably because of the strongest risk increase associated with the FCHL itself.
Analysis
Perform a panoramic analysis of this field.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free